Severe ifosfamide-induced neurotoxicity: a case report

Linares, S. Ramos; Atienza, J. Breña; Rudilla, Matilde Cháfer; Rull, Pablo Ríos; Rodríguez, Ana Cabello; Alonso, Javier Merino

doi:10.1007/s11096-009-9354-4

Cited by 7 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ifosfamide (IFOS), a structural analog of cyclophosphamide, is an alkylating chemotherapy agent used for a wide range of solid and hematologic malignancies. IFOS, a prodrug, is metabolized by the cytochrome P450 system into ifosforamide mustard (Furlanut and Franceschi, 2003; Ramos Linares et al, 2010). The quite common concerning side effects are myelosuppression and urotoxicity (Nicolao and Giometto, 2003).…”

Section: Introductionmentioning

confidence: 99%

Protective effects of caffeic acid phenethyl ester on ifosfamide-induced central neurotoxicity in rats

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Protective effects of caffeic acid phenethyl ester on ifosfamide-induced central neurotoxicity in rats

et al. 2013

View full text Add to dashboard Cite

show abstract

“…-Encephalopathy: from mild confusion or somnolence to more severe forms with hallucinations, psychosis, disorientation, memory loss, seizure, delirium, and rarely, coma and death. Incontinence, muscle twitching, focal motor deficits, facial nerve palsy, aphasia, mutism, and myoclonus are also common clinical symptoms [1,4,6]. Occurs in 10-30% of pediatric patients [6], has nonspecific CT and MRI features, but may have EEG triphasic waves (very common) [1,7].…”

Section: Ifosfamidementioning

confidence: 99%

“…Incontinence, muscle twitching, focal motor deficits, facial nerve palsy, aphasia, mutism, and myoclonus are also common clinical symptoms [1,4,6]. Occurs in 10-30% of pediatric patients [6], has nonspecific CT and MRI features, but may have EEG triphasic waves (very common) [1,7].…”

Section: Ifosfamidementioning

confidence: 99%

“…-Headaches (common) -Dizziness (uncommon) -Generalized tonic-clonic seizures: after 3-4 days of administration, anticonvulsant prophylaxis is recommended (uncommon) [1,4,6].…”

Section: Busulfanmentioning

confidence: 99%

“…-Pancerebellar syndrome: dysarthria, dysmetria, ataxia, nystagmus, and dysdiadochokinesia, due to direct damage of Purkinje cells (common) [1,4,6]. -Seizures and confusional syndromes: after intrathecal injection (common) [8].…”

Section: Cytarabinementioning

confidence: 99%

See 2 more Smart Citations

Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage

Alessi

Caroleo

Palma

et al. 2022

Cancers

View full text Add to dashboard Cite

Neurotoxicity caused by traditional chemotherapy and radiotherapy is well known and widely described. New therapies, such as biologic therapy and immunotherapy, are associated with better outcomes in pediatric patients but are also associated with central and peripheral nervous system side effects. Nevertheless, central nervous system (CNS) toxicity is a significant source of morbidity in the treatment of cancer patients. Some CNS complications appear during treatment while others present months or even years later. Radiation, traditional cytotoxic chemotherapy, and novel biologic and targeted therapies have all been recognized to cause CNS side effects; additionally, the risks of neurotoxicity can increase with combination therapy. Symptoms and complications can be varied such as edema, seizures, fatigue, psychiatric disorders, and venous thromboembolism, all of which can seriously influence the quality of life. Neurologic complications were seen in 33% of children with non-CNS solid malign tumors. The effects on the CNS are disabling and often permanent with limited treatments, thus it is important that clinicians recognize the effects of cancer therapy on the CNS. Knowledge of these conditions can help the practitioner be more vigilant for signs and symptoms of potential neurological complications during the management of pediatric cancers. As early detection and more effective anticancer therapies extend the survival of cancer patients, treatment-related CNS toxicity becomes increasingly vital. This review highlights major neurotoxicities due to pediatric cancer treatments and new therapeutic strategies; CNS primary tumors, the most frequent solid tumors in childhood, are excluded because of their intrinsic neurological morbidity.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Severe ifosfamide-induced neurotoxicity: a case report

Abstract: This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.

Cited by 7 publications

References 9 publications

Protective effects of caffeic acid phenethyl ester on ifosfamide-induced central neurotoxicity in rats

Protective effects of caffeic acid phenethyl ester on ifosfamide-induced central neurotoxicity in rats

Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About